1. Home
  2. INKT vs XLO Comparison

INKT vs XLO Comparison

Compare INKT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

N/A

Current Price

$8.61

Market Cap

53.7M

Sector

Health Care

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$7.65

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INKT
XLO
Founded
2017
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.7M
56.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INKT
XLO
Price
$8.61
$7.65
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
★ $44.00
$18.00
AVG Volume (30 Days)
10.2K
★ 11.6K
Earning Date
11-11-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
$3.55
Revenue Next Year
N/A
$9.26
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$8.48
$0.46
52 Week High
$15.27
$21.42

Technical Indicators

Market Signals
Indicator
INKT
XLO
Relative Strength Index (RSI) 33.82 40.49
Support Level N/A $7.29
Resistance Level $11.92 $9.19
Average True Range (ATR) 0.73 0.58
MACD -0.12 -0.07
Stochastic Oscillator 10.85 30.79

Price Performance

Historical Comparison
INKT
XLO

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: